IL33 and Alzheimer disease: The modest aggregate clinical effects seen in the current study with PF-06817024 are consistent with results from clinical trials with other IL-33 inhibitors such as itepekimab and etokimab; however, these trials were conducted in patients with asthma and AD, respectively [28, 32].